"Patients taking Wegovy for weight loss had a fivefold greater chance of developing non-arteritic anterior ischemic optic neuropathy (Naion) than the diabetes drug Ozempic, while men had a three times greater risk than women. These eye strokes cause sudden and usually permanent vision loss due to reduced blood flow to the optic nerve."
"Dr Edward Margolin, from the department of ophthalmology at the University of Toronto and one of the authors of the research, said Naion was likely to be a real side-effect of semaglutide, and faster, quicker or more aggressive weight loss would be likely to increase the risk of Naion."
"Although rare, affecting around one in 10,000 people who take semaglutide, there was a potential dose-dependent safety concern for the drug, the study found. Wegovy, Ozempic and Rybelsus made by Novo Nordisk all contain semaglutide, but have different dosages and formulations."
A study published in the British Journal of Ophthalmology found that patients taking Wegovy for weight loss face significantly elevated risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden and usually permanent vision loss. Wegovy users had a fivefold greater chance of developing NAION compared to Ozempic users, with men experiencing three times greater risk than women. Although rare, affecting approximately one in 10,000 semaglutide users, the research identified a potential dose-dependent safety concern. Researchers analyzed FDA adverse event reports from December 2017 to December 2024, comparing different formulations and dosages of semaglutide and tirzepatide. The findings suggest faster or more aggressive weight loss increases NAION risk.
#glp-1-receptor-agonists #semaglutide-safety #vision-loss-risk #weight-loss-medications #adverse-drug-effects
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]